Novel biomarker combination for the diagnosis, prognosis, stratification and/or monitoring of a therapy, of a cancer disease
AssigneeKing Faisal Specialist Hospital & Research Centre
InventorsHazem GHEBEH, Nasser ALRAJHI, Juamanah MIRZA
Life of this patent
Estimating the term…
Abstract
The present invention relates to a new method for the diagnosis, prognosis, stratification and/or monitoring of a therapy, of a cancer disease in a patient. The method is based on the determination of the level of CD3+ Tumor-Infiltrating Lymphocytes and CD24 expression. The new biomarker combination of the present invention allows diagnosing, prognosing, stratifying and/or monitoring of a therapy of various cancer diseases. Furthermore, provided are diagnostic kits for performing the non-invasive methods of the invention.
Claims20
A method for the diagnosis, prognosis, stratification and/or monitoring of a therapy, of a cancer disease in a subject, comprising the steps of:
- (a) Providing a biological sample from the subject;
- and
- (b) Determining the levels of at least two biomarkers in the biological sample, wherein the at least two biomarkers are CD3+ tumor-infiltrating lymphocytes (TIL) and CD24+ cells;
- wherein levels of the at least two biomarkers in the biological sample from the subject as determined in step (b) that are different from a healthy control or reference values are indicative of the presence of a cancer disease in the subject.
A method for evaluating the treatment success of a patient suffering from a cancer disease who received a cancer treatment, comprising the steps of:
- (a) Providing a biological sample from the subject;
- (b) Determining the levels of at least two biomarkers in the biological sample, wherein the at least two biomarkers are CD3+ tumor-infiltrating lymphocytes (TIL) and CD24+ cells;
- and
- (c) Comparing the levels of said at least two biomarkers as determined in (b) with a reference sample or reference values,
- wherein a decrease or an increase of the levels of the at least two biomarkers in the biological sample from said subject compared to said reference sample or reference values are indicative of the patient's response to said treatment.
Dependencies are inferred from the claim text.